Floatz logo

Orsythia Component Ethinyl Estradiol

Chronic Pain Syndrome

University of CagliariSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

91 Active assets in the Chronic Pain Syndrome cohort.

Asset / SponsorPhaseRating
(±)-Tramadol
EMS
Phase 4BBB
Lidocaine
National and Kapodistrian University of Athens
Phase 4BBB
METHADONE
Cari Health Inc.
Phase 4BBB
NEPENTHE
Bursa City Hospital
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Stanford University
Phase 4BBB

View all 50 →

Same molecule, other indications

Orsythia Component Ethinyl Estradiol is also rated in:

polycystic ovary syndromeActive
BBB
Indicative · Phase 4
75 / 100
View asset →
infertility disorderDormant
BB
Indicative · Phase 4
68 / 100
View asset →
migraine disorderDormant
BB
Indicative · Phase 3
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →